Cancer name Cervical Carcinoma
Cancer Type CESC
Immunotherapy type Cancer Vaccine
Treatment wE7-HSP70 vaccine
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature LDH
Official Symbol NA
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Lymphocytes from the mice vaccinated with uE7/HSP70 (67 ± 2.6) had a significantly higher specific cytolytic activity compared with those vaccinated with PBS (12.1% ± 0.70%), pcDNA3.1+ (negative plasmid control 19.1% ± 0.99%), pcDNA3.1+ wE7 (37.4% ± 2.09%), or pcDNA3.1+ uE7 (41.3% ± 2.2%) (P<0.05). However, no statistically significant difference was found between uE7/HSP70 and wE7/HSP70 groups as far as in cytolytic activity is concerned.
PMID 28919581
Title Antitumor Response to a Codon-Optimized HPV-16 E7/HSP71 Fusion Antigen DNA Vaccine